Application Nr Approved Date Route Status External Links
BLA125387 None Intravitreal None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Eylea Is Indicated For The Treatment Of: Eylea Is A Vascular Endothelial Growth Factor (Vegf) Inhibitor Indicated For The Treatment Of Patients With: Neovascular (Wet) Age-Related Macular Degeneration (Amd) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (Rvo) ( 1.2 ) Diabetic Macular Edema (Dme) ( 1.3 ) Diabetic Retinopathy (Dr) ( 1.4 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (Amd) 1.2 Macular Edema Following Retinal Vein Occlusion (Rvo) 1.3 Diabetic Macular Edema (Dme) 1.4 Diabetic Retinopathy (Dr)

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Aflibercept

Comments